FindTrial
Sign In

Retrospective study of Initial Acute Decline in eGFR by SGLT2-inhibitor

Retrospective study of Initial Acute Decline in eGFR after SGLT2-inhibitor Therapy in Patients with Type-2 Diabetes Mellitus and CKD Stage-3b - Retrospective study of IAD-eGFR by SGLT2i in T2DM and CKD 3b

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000039903
Enrollment
100
Registered
2020-06-01
Start date
2019-11-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Sponsors

Jinnouchi Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: T2DM CKD 3b SGLT2i therapy for more than 6 months

Exclusion criteria

Exclusion criteria: Type 1 DM unstable condition cancer infection

Design outcomes

Primary

MeasureTime frame
We retrospectively investigated how much and how frequently IAD-eGFR occurs in T2DM patients with CKD Stage-3b in the real clinical practice.—

Countries

Japan

Contacts

Public ContactSeigo Sugiyama

Jinnouchi Hospital Diabetes Care Center

seigosugiyama@jinnouchi.or.jp096-363-0011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026